British Journal of Medical & Surgical Urology
Volume 2, Issue 4 , Pages 171-173 , July 2009

Patient designed therapy provides possible “natural” selection evidence for testosterone as differentiating agent for high-grade prostate cancer

  • G.L. Shaw

      Affiliations

    • St Barts & The London Hospitals, London, United Kingdom
    • Corresponding Author InformationCorresponding author at: St Barts & The London Hospitals, London, United Kingdom.
    • ,
  • M.E. Emberton

      Affiliations

    • University College Hospital London, United Kingdom
    • ,
  • R. Morgan

      Affiliations

    • Royal Free Hospital, United Kingdom
    • ,
  • D. Berney

      Affiliations

    • St Barts & The London Hospitals, London, United Kingdom
    • Wolfson Institute and Institute of Cancer, Queen Mary University of London, United Kingdom
    • ,
  • J. Cuzick

      Affiliations

    • Wolfson Institute and Institute of Cancer, Queen Mary University of London, United Kingdom
    • ,
  • R.T.D. Oliver

      Affiliations

    • University College Hospital London, United Kingdom

Received 15 November 2008 ,Accepted 14 December 2008.

References 

  1. Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, et al. International study into the use of intermittent hormone therpapy in the treatment of carcinoma of the prostate: a meta analysis of 1446 patients. BJU International. 2007;99:1056–1065
  2. Huggins C, Hodges C. Studies on prostatic cancer 1: the effect of castration of estrogen and the androgen injection on serum phosphatases in metastatic carcioma of the prosate. Cancer Research. 1941;I:293–297
  3. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Research. 1999;59(September (17)):4161–4164
  4. Slater S, Oliver RT. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs & Aging. 2000;17(6):431–439
  5. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. European Urology. 2006;50(5):935–939
  6. Morales A, Connolly JG, Burr RC, Bruce AW. The use of radioactive phosphorous to treat bone pain in metastatic carcinoma of the prostate. Canadian Medical Association Journal. 1970;103:372–373
  7. Morales A. Testosterone and prostate health: debunking myths demands evidence, caution, and good clinical judgment. European urology. 2006;50:895–897
  8. San Francisco IF, Regan MM, Dewolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. Journal of Urology. 2006;175(4):1341–1345[discussion 1345–6]
  9. Kirby R, Robertson C, Turkes A, Griffiths K, Denis LJ, Boyle P, et al. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland International Prostate Health Council (IPHC) Trial Study Group. The Prostate. 1999;40(July (2)):105–114
  10. San Francisco IF, Regan MM, DeWolf WC, Olumi AF. Morales, A., Re: low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. Journal of Urology. 2006;175:1341–1346[The Journal of Urology 2006 Dec;176(6 Pt 1):2746; author reply]
  11. Stoll BA. Hypothesis: breast cancer regression under oestrogen therapy. British Medical Journal. 1973;3(August (5877)):446–450
  12. Cusick JGF, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, et al. On behalf of the Transatlantic Prostate Group. Long-term outcome among men with conservatively treated localised prostate cancer. British Journal of Cancer. 2006;95(November (9)):1186–1194

PII: S1875-9742(08)00154-7

doi: 10.1016/j.bjmsu.2008.12.005

British Journal of Medical & Surgical Urology
Volume 2, Issue 4 , Pages 171-173 , July 2009

Article Tools